Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment

NCT05113290 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Recombinant Human Adenovirus Type 5 injection
DRUG: Sorafenib

Sponsor

First Affiliated Hospital Xi'an Jiaotong University